Source comparison
Melanotan-1 Oral vs Injectable: Comparison
The following table compares the key pharmacological and practical differences between oral and injectable Melanotan-1 for research applications. Bioavailability 85–95% 5–10% (3% without enteric coating) Injectable delivers 10–15× higher systemic exposure per
This comparison does not assign a generated winner or score.
- The following table compares the key pharmacological and practical differences between oral and injectable Melanotan-1 for research applications.
- Bioavailability
- 85–95%
- 5–10% (3% without enteric coating)
- Injectable delivers 10–15× higher systemic exposure per mg
- Typical Dose per Administration
- 0.5–1.0 mg
- 10–20 mg
- Oral requires 10–20× more peptide to match injectable plasma levels
- Onset to Peak Plasma Level
- 60–90 minutes
- 90–180 minutes (if absorbed)
- Injectable reaches therapeutic levels faster and more reliably
- Dosing Frequency (Loading Phase)
- Every 24–48 hours
- Daily to twice daily
- Oral protocols require more frequent dosing due to absorption variability
- Storage (Pre-Use)
- Lyophilized powder: −20°C for years, room temp for months
- Enteric capsules: room temp, avoid moisture
- Injectable lyophilized form is more stable long-term
- Reconstitution Required
- Yes. Bacteriostatic water, <60 seconds
- No
- Oral is simpler but sacrifices bioavailability
- Refrigeration After Preparation
- Yes. 2–8°C, use within 28 days
- Not applicable
- Injectable requires cold chain after reconstitution
- Inter-Individual Dosing Variability
- Low. Consistent absorption from subcutaneous depot
- High. Gastric pH, enzyme activity, and transit time vary significantly
- Injectable protocols produce more reproducible outcomes
- Technique Requirement
- Subcutaneous injection with insulin syringe (29–31G)
- Oral ingestion
- Oral is easier but far less effective
- Professional Assessment
- Injectable is the gold standard for research applications requiring dose precision, reproducibility, and measurable melanogenesis. Oral formulations are pharmacologically viable but require 10–20× higher peptide quantities and introduce significant variability. Rarely used in controlled studies.